Anti-Pde2a antibody R2G
Antibody raised against Pde2a, a cyclic nucleotide phosphodiesterase specific for second messengers cAMP and cGMP.
Catalogue number crb2005717d/R2G Antibody Anti-Pde2a antibody R2G Antigen Peptide KLH conjugated synthetic peptide crb1200926 Protein ID UniProtKB - Q922S4 Aliases cGMP-dependent 3',5'-cyclic phosphodiesterase, Cyclic GMP-stimulated phosphodiesterase, CGS-PDE, cGSPDE Cross-Reactivity Mouse Host Species Rabbit Antibody Type Polyclonal Concentration 2.0 mg/mL Glycine (R2G) Target Pde2a Family Cyclic nucleotide phosphodiesterase family. PDE2 subfamily. Storage This material is supplied in PBS containing 0.01% sodium azide and 1% trehalose. The product should be stored at +4°C for short term storage and -20°C for long term storage. Avoid repeated freeze/thaw cycles.
PDEs are a family of phosphohydrolyases, used to catalyse hydrolysis of 3’ cyclic phosphate bonds in the second messengers adenosine and guanine 3’, 5’ cyclic monophosphates (cAMP and cGMP). Physiologically, Pde2a is a locus for communication between cAMP and cGMP signalling pathways, regulating this process through degradation of cAMP and cGMP. This is particularly noteworthy in cells where cAMP and cGMP regulate opposing cell functions.
Pde2a is expressed both in the periphery and central nervous system, but is found in highest concentration in the brain; implying that Pde2a is necessary in regulation of interneuronal cAMP and cGMP involved in emotion, sensory perception and memory. Alteration in cyclic nucleotide signalling is shown cause depression, bipolar disorder and schizophrenia; hence Pde2a, a molecule used to break down cyclic nucleotides, has the potential to be a novel biomarker or therapeutic target for such psychiatric conditions.